Ge Long Hui·2025-11-11 02:37Core Viewpoint - The report from Credit Lyonnais indicates that JD Health is expected to maintain robust growth in drug sales, driven by original drugs and chronic disease medications, with a projected year-on-year increase of over 30% in Q3 [1] Group 1: Revenue and Growth Projections - JD Health's total revenue for Q3 is anticipated to grow by 25% year-on-year, reaching 16.6 billion yuan [1] - The adjusted EBIT is expected to rise by over 40% year-on-year to 1.2 billion yuan [1] - For the second half of the year, revenue is projected to increase by 20% year-on-year, with Q4 expected to show a year-on-year growth of 16% [1] Group 2: Long-term Forecasts - The revenue growth forecast for the full year of 2025 has been raised to 22%, with an EBIT margin expected to be 5.7%, up from the previous forecast of 5.0% [1] - The adjusted net profit forecasts for the current and next year have been increased by 5% and 4%, respectively [1] - The target price for JD Health has been raised from 64 HKD to 66 HKD, maintaining an "outperform" rating [1]